专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011024620A1 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗生物药物组合物
公开(公告)号：WO2011024620A1
公开(公告)日：2011-03-03
申请号：PCT/JP2010/063230
申请日：2010-07-29
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD. , KOBAYASHI, Hirokazu , KUBOTA, Nobuo
发明人： KOBAYASHI, Hirokazu , KUBOTA, Nobuo
IPC分类号： A61K31/4178 , A61P17/00 , A61P31/10 , A61K47/08
CPC分类号： A61K31/4178 , A61K9/0014 , A61K47/08 , A61P17/00 , A61P31/10
摘要： A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof; and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R 1 =R 2 =a chlorine atom: where R 1 and R 2 each independently represents a hydrogen atom or a halogen atom, and at least one of R 1 and R 2 represents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage.
摘要翻译：一种药物组合物，其包含1）由以下通式（1）表示的化合物和/或其盐; 和2）酮如甲基乙基酮。优选地，由以下通式（1）表示的化合物是卢立康唑，其中R 1 = R 2 =氯原子：其中R 1和R 2各自独立地表示氢原子或卤素原子，并且R 1和R 2中的至少一个表示卤素原子。本发明提供了在低温或高温储存中对通式（1）表示的化合物和/或其盐的增溶稳定性优异的制剂。

2. 发明申请

WO2010117089A3 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗氧化药物组合物
公开(公告)号：WO2010117089A3
公开(公告)日：2010-12-09
申请号：PCT/JP2010056881
申请日：2010-04-09
申请人： POLA PHARMA INC , NIHON NOHYAKU CO LTD , KOBAYASHI HIROKAZU , KOSUGI EIKO , KUBOTA NOBUO
发明人： KOBAYASHI HIROKAZU , KOSUGI EIKO , KUBOTA NOBUO
IPC分类号： A61K9/08 , A61K9/00 , A61K9/70 , A61K31/4178
CPC分类号： A61K31/4178 , A61K9/0014 , A61K9/08 , A61K9/7015 , A61K47/08 , A61K47/10 , A61K47/14
摘要： In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60°C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20°C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5°C. for 2 weeks after manufacture.
摘要翻译：在含有5质量％以上的卢立克唑等化合物和/或其盐的外用药物组合物中含有丙酮，聚氧乙烯烷基（碳原子数为8〜30），以及 /或聚氧乙烯烯基（具有8至30个碳原子）醚。本发明提供使用克罗他米通以外的溶剂，碳酸亚丙酯和N-甲基-2-吡咯烷酮作为用于增溶和空间稳定的溶剂的制剂，其具有以下性质：1）当通式（1）和 /或其盐具有立体异构体，在60℃的保存条件下产生的化合物和/或其盐的立体异构体的量。在保存开始时相对于化合物和/或其盐的总质量为3质量％以下为1质量％以下; 2）当在20℃的恒定温度下保存时，制剂处于澄清的液体状态。在制造之后立即; 和3）当制剂在5℃保存时，没有晶体沉积。在制造后2周。

3. 发明申请

WO2011155640A1 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗生物药物组合物
公开(公告)号：WO2011155640A1
公开(公告)日：2011-12-15
申请号：PCT/JP2011/063860
申请日：2011-06-10
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD. , KUBOTA, Nobuo , KOBAYASHI, Hirokazu , MASUDA, Takaaki
发明人： KUBOTA, Nobuo , KOBAYASHI, Hirokazu , MASUDA, Takaaki
IPC分类号： A61K9/06 , A61K9/08 , A61K9/10 , A61K9/12 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/385 , A61K31/4178 , A61K47/10 , A61K47/14 , A61K47/34 , A61K47/44
CPC分类号： A61K31/4178 , A61K9/0014 , A61K9/08 , A61K31/385 , A61K47/10 , A61K47/14 , A61K47/22
摘要： An object is to provide a medicament preparation which is excellent in the solubilization stability in relation to a compound represented by the general formula (1) during the storage in a low temperature region and a high temperature region. The present invention resides in a pharmaceutical composition comprising 1) the compound represented by the general formula (1) and/or a salt thereof and 2) a polyhydric alcohol derivative. General formula (1) (In the formula, R 1 , R 2 independently represent hydrogen atom or halogen atom respectively, and at least one of R 1 , R 2 is halogen atom.)
摘要翻译：本发明提供一种药物制剂，其在低温区域和高温区域的储存过程中，相对于由通式（1）表示的化合物的溶解稳定性优异。本发明涉及一种药物组合物，其包含1）由通式（1）表示的化合物和/或其盐和2）多元醇衍生物。通式（1）（式中，R 1，R 2分别独立地表示氢原子或卤原子，R 1，R 2中的至少一个为卤素原子）

4. 发明申请

WO2012101980A1 SOLID-LIQUID SEPARATION DEVICE 审中-公开
标题翻译：固液分离装置
公开(公告)号：WO2012101980A1
公开(公告)日：2012-08-02
申请号：PCT/JP2012/000237
申请日：2012-01-17
申请人： AMUKON KABUSHIKI KAISHA , KANEKO, Kazuo , TEZUKA, Yusuke , NAKAMURA, Yoshitaka , KADOWAKI, Yuki , KOBAYASHI, Hirokazu
发明人： KANEKO, Kazuo , TEZUKA, Yusuke , NAKAMURA, Yoshitaka , KADOWAKI, Yuki , KOBAYASHI, Hirokazu
IPC分类号： B30B9/26 , B30B9/12
CPC分类号： B30B9/121 , B01D25/127 , B01D29/35 , B01D29/46 , B01D29/52 , B01D29/6476 , B01D29/828 , B30B9/12 , B30B9/14 , B30B9/26
摘要： A solid-liquid separation device includes a plurality of fixed members and movable members that are movably disposed between the adjacent fixed members, and moreover a screw extending through the fixed members and the movable members in a state where the screw is not in contact with the fixed members and the movable members. The screw is rotationally driven about a center axis line thereof. Following the rotation of the screw, an object to be treated that has penetrated into a solid-liquid separation portion demarcated by the fixed members and the movable members is caused to move toward an outlet of the solid-liquid separation portion, a filtrate separated from the object is discharged to the outside of the solid-liquid separation portion through filtrate discharge gaps between the fixed members and the movable members, and the object that has a reduced liquid content ratio is discharged from the outlet to the outside of the solid-liquid separation portion. In order to increase significantly a dewatering ratio of the object, the movable members are formed to move while penetrating closer to the center axis line of the screw than an outer circumferential edge of the blade of the screw, without coming into contact with the screw.
摘要翻译：固液分离装置包括可移动地设置在相邻的固定构件之间的多个固定构件和可动构件，以及在螺钉不与其接触的状态下延伸穿过固定构件和可动构件的螺钉固定构件和可移动构件。螺杆围绕其中心轴线被旋转地驱动。在螺杆旋转之后，使已经渗透到由固定部件和可移动部件划分的固液分离部分中的待处理物体朝向固液分离部分的出口移动，滤液与物体通过固定部件和可动部件之间的滤液排出间隙排出到固液分离部分的外部，并且具有降低的液体比例的物体从出口到固体液体的外部排出分离部分。为了显着提高物体的脱水率，可移动构件形成为在与螺钉的螺钉接触的同时比螺杆的叶片的外周边缘更靠近螺钉的中心轴线的方向移动。

5. 发明申请

WO2010117089A2 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗生物药物组合物
公开(公告)号：WO2010117089A2
公开(公告)日：2010-10-14
申请号：PCT/JP2010/056881
申请日：2010-04-09
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD. , KOBAYASHI, Hirokazu , KOSUGI, Eiko , KUBOTA, Nobuo
发明人： KOBAYASHI, Hirokazu , KOSUGI, Eiko , KUBOTA, Nobuo
IPC分类号： A61K9/08
CPC分类号： A61K31/4178 , A61K9/0014 , A61K9/08 , A61K9/7015 , A61K47/08 , A61K47/10 , A61K47/14
摘要： In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60°C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20°C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5°C. for 2 weeks after manufacture.
摘要翻译：在含有5质量％以上的化合物如卢立康唑和/或其盐的外用药物组合物中，丙酮，聚氧乙烯烷基（碳原子数为8〜30）的醚，以及 /或聚氧乙烯烯基（碳原子数为8〜30）的醚。本发明提供使用克罗他米通以外的溶剂，碳酸丙烯酯和N-甲基-2-吡咯烷酮作为增溶和空间稳定化溶剂的制剂，具有以下性质：1）当由通式（1）表示的化合物和 /或其盐具有立体异构体，在60℃的保存条件下产生的化合物和/或其盐的立体异构体的量。相对于保存开始时的化合物和/或其盐的总质量，3周为1质量％以下。 2）当在20℃的恒定温度下保存时，制剂处于澄清的液体状态。制造后立即生产; 和3）当制剂在5℃保存时，不沉积晶体。制造后2周。

6. 发明申请

WO2003088615A3 MOBILE NODE, ROUTER, SERVER AND METHOD FOR MOBILE COMMUNICATIONS UNDER IP VERSION 6 (IPV6) PROTOCOL 审中-公开
公开(公告)号：WO2003088615A3
公开(公告)日：2003-10-23
申请号：PCT/JP2003/004898
申请日：2003-04-17
申请人： MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. , FUNABIKI, Makoto , IKEDA, Shinkichi , MATSUMOTO, Taisuke , KIMURA, Yasunari , KOBAYASHI, Hirokazu
发明人： FUNABIKI, Makoto , IKEDA, Shinkichi , MATSUMOTO, Taisuke , KIMURA, Yasunari , KOBAYASHI, Hirokazu
IPC分类号： H04L29/06
摘要： In a mobile communication system supported with IP version 6, a mobile node (10) measures at least one of a hop number or communication delay time to a belonging home agent (11). When the result of measurement is equal to or greater than a predetermined value, registration deletion is requested to the belonging home agent (11) while registration is requested to a new home agent (14). The belonging home agent (11) deletes the registration of mobile node (10), and the new home agent (14) registers the mobile node. This can reduce the load on an IP network (18) and decrease data delay.

7. 发明申请

WO2011089791A1 IMAGING DEVICE AND DRIVING METHOD FOR SOLID-STATE IMAGE SENSOR 审中-公开
标题翻译：用于固态图像传感器的成像装置和驱动方法
公开(公告)号：WO2011089791A1
公开(公告)日：2011-07-28
申请号：PCT/JP2010/071945
申请日：2010-12-01
申请人： CANON KABUSHIKI KAISHA , KOBAYASHI, Hirokazu
发明人： KOBAYASHI, Hirokazu
IPC分类号： H04N5/361 , H04N5/374
CPC分类号： H04N5/3591 , H01L27/14609 , H04N5/3745
摘要： An imaging device comprises a solid-state image sensor including a plurality of unit pixels, and a driving unit. Each unit pixel includes a photo-electric converter that converts incident light into a signal charge, a holding unit that temporarily holds the signal charge obtained by the photo-electric converter, a first transfer gate arranged between the photo-electric converter and the holding unit, that transfers the signal charge to the holding unit, a charge-voltage converter that converts the signal charge into a voltage signal, and a second transfer gate arranged between the holding unit and the charge-voltage converter, that transfers the signal charge to the charge-voltage converter, and that is in a non-conductive state in the case where an image capturing operation is performed in the photo-electric converter. The driving unit drives the solid-state image sensor so as to supply three or more mutually different electric potentials to the first transfer gate.
摘要翻译：成像装置包括具有多个单位像素的固态图像传感器和驱动单元。每个单位像素包括将入射光转换为信号电荷的光电转换器，暂时保持由光电转换器获得的信号电荷的保持单元，布置在光电转换器和保持单元之间的第一传输门，其将信号电荷传送到保持单元，将信号电荷转换为电压信号的电荷 - 电压转换器，以及布置在保持单元和充电 - 电压转换器之间的第二传输门，其将信号电荷传送到电荷转换器，并且在光电转换器中执行图像捕获操作的情况下处于非导通状态。驱动单元驱动固态图像传感器，以便向第一传输门提供三个或更多个相互不同的电位。

8. 发明申请

WO2010117091A2 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗生物药物组合物
公开(公告)号：WO2010117091A2
公开(公告)日：2010-10-14
申请号：PCT/JP2010/056884
申请日：2010-04-09
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD. , KOBAYASHI, Hirokazu , KOSUGI, Eiko , KUBOTA, Nobuo
发明人： KOBAYASHI, Hirokazu , KOSUGI, Eiko , KUBOTA, Nobuo
IPC分类号： A61K9/08
CPC分类号： A61K9/7015 , A61K9/0014 , A61K9/08 , A61K31/4178
摘要： In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25°C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a steroisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20°C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5°C. for 2 weeks after manufacture.
摘要翻译：在含有诸如卢立康唑和/或其盐的化合物的外用药物组合物中，包含在1atm和25℃处于液体状态的高级醇。和/或二元酸的二酯，条件是不含碳酸二酯，聚氧乙烯烷基醚和/或聚氧乙烯烯基醚。本发明提供使用克罗他米通以外的溶剂，碳酸丙烯酯和N-甲基-2-吡咯烷酮作为增溶和空间稳定化的溶剂的制剂，具有以下性质：1）当由通式（1）表示的化合物和 /或其盐具有立体异构体，在60℃的保存条件下生产的化合物和/或其盐的立体异构体的量为3周时相对于总质量为1质量％化合物和/或其盐在保存开始时; 2）当在20℃的恒定温度下保存时，制剂处于澄清的液体状态。制造后立即生产; 和3）当制剂在5℃保存时，不沉积晶体。制造后2周。

9. 发明申请

WO2005104458A1 WIRELESS COMMUNICATION DEVICE, WIRELESS COMMUNICATION PROGRAM AND ROUTE SEARCH METHOD 审中-公开
标题翻译：无线通信设备，无线通信程序和路由搜索方法
公开(公告)号：WO2005104458A1
公开(公告)日：2005-11-03
申请号：PCT/JP2005/007744
申请日：2005-04-18
申请人： MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. , KOBAYASHI, Hirokazu , KAWAHARA, Toyoki , KANAZAWA, Takeshi , OKA, Naoto
发明人： KOBAYASHI, Hirokazu , KAWAHARA, Toyoki , KANAZAWA, Takeshi , OKA, Naoto
IPC分类号： H04L12/56
CPC分类号： H04L45/00 , H04L45/34
摘要： Provided are a route request information recording section (107) recording identifiers specifying wireless communication devices as targets of route search on an ad-hoc network, a route control message generation processing section (106) including the identifiers of the wireless communication devices one to a plurality in the number recorded therein and for generating a route request message, a transmitting section (103) for broadcasting the route request message generated in the same, and a route control message reception processing section (108) for receiving a route response message transmitted from the wireless communication device as a target of route search, which has received the route request message and deleting the identifier of the wireless communication device as the target of route search from the route request information recording section (107). Accordingly, a plurality of wireless communication device identifiers on a target of route can be put together on one route request message.
摘要翻译：提供了一种在ad-hoc网络上记录指定无线通信设备作为路由搜索的目标的标识符的路由请求信息记录部分，包括无线通信设备的标识符的路由控制消息产生处理部分，多个在其中记录的号码和用于产生路由请求消息的发送部分（103），用于广播其中生成的路由请求消息的发送部分（103）和用于接收从其发送的路由响应消息的路由控制消息接收处理部分所述无线通信装置作为路线搜索的目标，已经从所述路线请求信息记录部分接收到所述路线请求消息并删除作为路线搜索的目标的所述无线通信装置的标识符。因此，可以在一个路由请求消息上将路由目标上的多个无线通信设备标识符放在一起。

10. 发明申请

WO2010117091A3 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗氧化药物组合物
公开(公告)号：WO2010117091A3
公开(公告)日：2010-12-02
申请号：PCT/JP2010056884
申请日：2010-04-09
申请人： POLA PHARMA INC , NIHON NOHYAKU CO LTD , KOBAYASHI HIROKAZU , KOSUGI EIKO , KUBOTA NOBUO
发明人： KOBAYASHI HIROKAZU , KOSUGI EIKO , KUBOTA NOBUO
IPC分类号： A61K9/08 , A61K9/00 , A61K9/70 , A61K31/4178
CPC分类号： A61K9/7015 , A61K9/0014 , A61K9/08 , A61K31/4178
摘要： In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25°C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a steroisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20°C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5°C. for 2 weeks after manufacture.
摘要翻译：含有卢立康唑等化合物和/或其盐的外用药物组合物含有在1atm，25℃下为液态的高级醇。和/或二元酸的二酯，条件是不包括碳酸二酯，以及聚氧乙烯烷基醚和/或聚氧乙烯链烯基醚。本发明提供一种使用克罗他米通以外的溶剂，碳酸亚丙酯和N-甲基-2-吡咯烷酮作为用于增溶和空间稳定的溶剂的制剂，其具有以下性质：1）当通式（1）和 /或其盐具有立体异构体时，在60℃的保存条件下制备的化合物和/或其盐的立体异构体的量相对于总质量为1质量％保存开始时的化合物和/或其盐; 2）当在20℃的恒定温度下保存时，制剂处于澄清的液体状态。在制造之后立即; 和3）当制剂在5℃保存时，没有晶体沉积。在制造后2周。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式